RESEARCH PEPTIDE FUNDAMENTALS / COLOPHON
Contact the Editorial Desk
Correspondence on citations, corrections, and newly published research — exactly what a skeptic's scorecard exists to receive.
Correspondence
Best Peptide is glad to hear about the research record itself: a citation quoted inaccurately, a clinical trial that has published new results, a regulatory status update, or a peer-reviewed study on CJC-1295, ipamorelin, KPV, retatrutide, or semaglutide that belongs on the references page. Corrections that improve the accuracy or currency of the scorecard are the most useful messages it receives.
The most actionable submissions name the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed change can be checked against its source before anything is revised.
Editorial mailbox: editors@bestpeptide.org
What the scorecard cannot do
Best Peptide is a graded reading of literature, not a clinical service or a seller, so it cannot advise on or recommend human use of any peptide covered here, suggest a dose or schedule for any individual, judge whether a cited finding applies to a specific person's situation, or help locate, source, or purchase any compound from any supplier. It cannot guide anyone toward prescription medicine outside a licensed prescriber relationship, and it cannot advise athletes on anti-doping status for any compound.
Semaglutide medicines require a prescription; research-labelled semaglutide is also sold and is distinct from either FDA-approved medicines or compounded preparations with no FDA approval. Retatrutide is investigational and has no FDA-approved prescription product; research-labelled sales are separate from registered clinical trials. CJC-1295, ipamorelin, and KPV are unapproved research chemicals. A reader seeking clinical guidance should consult a licensed healthcare provider. Replies to correspondence are not guaranteed and may lag.